Abstract 232P
Background
An ongoing field of research examines the use of the proteasome genes as prognostic biomarkers in cancer. The cross talk between such machinery and VHL is well rectified, so it is of a great interest to study the prognostic utility of the 20S proteasome gene family in VHL-mutated ccRCC cohort.
Methods
Clinical and transcriptomics data of VHL-mutated ccRCC patients were obtained from the Cancer Genome Atlas Program (TCGA). A total of 11 genes of the 20S proteasome β-subunit (PSMB1-11) were retrieved and tested for their prognostic potential using multivariate Cox logistic regression. The immune suppressive landscape was viewed through the assessment of M2 macrophages (M2M), cancer-associated fibroblasts (CAF), T-regulatory cells (Tregs), and myeloid-derived suppressor cells (MDSC) infiltration using xCell. Correlations with T-cell exhaustion genes were performed additionally.
Results
A total of six genes exhibited significant prognostic indicators, including PSMB1 (HR: 2.113, 95% CI: 1.101-4.056, P = .024), PSMB2 (HR: 2.303, 95% CI: 1.168-4.542, P = .016), PSMB4 (HR: 2.165, 95% CI: 1.075-4.361, P = .031), PSMB6 (HR: 2.956, 95% CI: 1.458-5.998, P = .003), PSMB7 (HR: 2.168, 95% CI: 1.127-4.170, P = .020), and PSMB10 (HR: 2.227, 95% CI: 1.109-4.469, P = .024). Immunosuppressive cells infiltration analysis revealed the following significant correlations (P < .05): PSMB1: MDSC (ρ = 0.316), PSMB2: M2M (ρ = 0.242) and MDSC (ρ = 0.268), PSMB4: M2M (ρ = 0.159) and MDSC (ρ = 0.372), PSMB6: M2M (ρ = 0.247) and MDSC (ρ = 0.412), PSMB7: MDSC (ρ = 0.298), and PSMB10: M2M (ρ = 0.283) and MDSC (ρ = 0.271). No significant correlations were observed in CAF infiltration. Surprisingly, all the markers negatively correlated with Tregs infiltration. The prognostic genes followed a unified pattern of correlation with T-cell exhaustion genes in which positive significant correlations to CTLA4, LAG3, and GZMB were observed. In contrast, all the markers negatively correlated with CD274 (PD-L1) expression.
Conclusions
Several members of the 20S proteasome β-subunit gene family exhibit a prognostic role in VHL-mutated ccRCC and induce an immunosuppressive tumor microenvironment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
529P - Ramucirumab plus docetaxel after combination chemoimmunotherapy in patients with non-small cell lung cancer: A prospective observational study
Presenter: Tadaaki Yamada
Session: Poster Display
Resources:
Abstract
530P - MYC recruits tumor-associated macrophage to sustain metastatic malignancy of lung adenocarcinoma micropapillary subtype through epigenetic reprogramming
Presenter: Xuming Song
Session: Poster Display
Resources:
Abstract
531P - Effect of combinational targeted therapy for AXL and ATR against malignant mesothelioma cells
Presenter: Soichi Hirai
Session: Poster Display
Resources:
Abstract
532P - The changes of the serum SMRP levels is useful to predict the antitumor efficacy of ipilimumab plus nivolumab combination therapy in patients with malignant pleural mesothelioma
Presenter: Taiichiro Otsuki
Session: Poster Display
Resources:
Abstract
533P - Efficacy in the elderly NSCLC patients in SCORPION study: Phase II study of DTX plus RAM following platinum-based chemotherapy plus ICIs
Presenter: Teppei Yamaguchi
Session: Poster Display
Resources:
Abstract
534P - DSC2 promotes the proliferation, metastasis and drug resistance of lung cancer by activating the PI3K/AKT pathway
Presenter: Qi Li
Session: Poster Display
Resources:
Abstract
535P - Alteration in NKX2-1 CN reshapes the oncogenic, immunologic, and prognostic landscapes in NSCLC
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
536P - The evaluation and long-term outcome of pulmonary metastasectomy for osteosarcoma: A 20-year experience of Shanghai Rujin Hospital
Presenter: Zhusheng Zhang
Session: Poster Display
Resources:
Abstract
537P - The impact of treatment-free interval on patient outcome after pulmonary metastasectomy for sarcoma
Presenter: Po-Kuei Hsu
Session: Poster Display
Resources:
Abstract
538P - First-line chemoimmunotherapy for metastatic thymic carcinoma
Presenter: Victoria Andreas
Session: Poster Display
Resources:
Abstract